Dive deep into the evolving world of urothelial carcinoma treatment in this must-watch discussion hosted by Vic Senese, RN, BSN, FAUNA of UroNurse. Join renowned experts Jason M. Hafron, MD (urologic oncologist specializing in bladder, prostate, and kidney cancers) and Shilpa Gupta, MD (Director of Genitourinary Medical Oncology at Cleveland Clinic) as they explore refining treatment strategies for advanced and metastatic urothelial carcinoma (bladder cancer).In this episode, discover the latest insights on shifting paradigms beyond traditional platinum-based chemotherapy, including the role of maintenance therapy like avelumab, groundbreaking combinations such as enfortumab vedotin plus pembrolizumab (Padcev + Keytruda) from trials like EV-302/KEYNOTE-A39, subgroup considerations (e.g., diabetes impact on outcomes), precision immuno-oncology approaches, biomarker-driven decisions, and future directions to improve survival and quality of life for patients with locally advanced or metastatic disease.Whether you're a urology nurse, urologist, oncologist, medical student, or patient/caregiver seeking expert perspectives on bladder cancer treatment advances, this conversation covers practical clinical implications, emerging therapies, sequencing challenges, and personalized strategies in 2026 and beyond.Hosted by Vic Senese, RN, BSN, FAUNA – Subscribe to my channel at https://www.youtube.com/@UroNurse1 for weekly urology education, guidelines, clinical updates, and tips from leading experts! The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions.
